ReviewCureus2024
A Narrative Review of the Role of Blood Biomarkers in the Risk Prediction of Cardiovascular Diseases.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Unravelling the Link between Inflammatory Biomarkers and Coronary Artery Ectasia Severity: A Systematic Review and Meta-Analysis.Cardiology · 2026Pooled it
- Association of Hypertension Severity with 30-Day Major Adverse Cardiovascular Events in Patients with Intermediate High-Sensitivity Cardiac Troponin I.The western journal of emergency medicine · 2026Article
- Association Between the Ratio of Blood Urea Nitrogen to Serum Albumin, All-Cause and Cardiovascular Mortality, and Cardiovascular Disease Risk in USA Adults: An Observational Cohort Analysis.Health science reports · 2026Article
- Heart-Brain Axis in Viral Myocarditis: Shared Cytokine Pathways, Blood-Brain Barrier Crosstalk, and Neuroinflammatory Consequences.International journal of molecular sciences · 2026Review
- Predictive value of miR-193a-5p combined with VEGFB in the diagnosis and prognosis of CHD.Journal of cardiothoracic surgery · 2026Article
- Association between neutrophil/ high-density lipoprotein cholesterol ratio and BMI in three Argentinean Indigenous communities.Biochemistry and biophysics reports · 2025Article
- A sex-specific genome-wide association study of blood lipid levels in All of Us.medRxiv : the preprint server for health sciences · 2025Article
- Post-translational modifications orchestrate mTOR-driven cell death in cardiovascular disease.Frontiers in cardiovascular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) is a global health crisis and a leading cause of morbidities and mortalities. Biomarkers whose evaluation would allow the detection of CVD at an early stage of development are actively sought. Biomarkers are objectively measured as indicators of health, disease, or response to an exposure or intervention, including therapeutic interventions. Hence, this review aims to identify biomarkers that can help predict CVD risk in the healthy population. This helps with risk prediction and is crucial for advancing preventive cardiology and improving clinical outcomes in a wide range of patient populations. Biomarkers such as atherogenic lipoproteins, fibrinogen, homocysteine, and thyroid-stimulating hormone (TSH) have been linked to CVD risk factors, including dyslipidemia, hypertension, diabetes, and obesity. When combined with conventional biomarkers, inflammatory markers such as C-reactive protein (CRP) can enhance risk prediction. However, biomarkers such as high-sensitivity troponin T (hsTnT) and N-terminal proBNP (NT-proBNP) are widely used as diagnostic biomarkers for heart failure (HF) and cardiac dysfunction, as they are released only after one to two hours of cardiovascular event occurrence. Myeloperoxidase (MPO) and procalcitonin (PCT) have developed into promising new biomarkers for the early detection of systemic bacterial infections as inflammatory markers, which are better diagnostic tools than screening. Combining biomarkers can improve test accuracy, but the best combinations for diagnosis or prognosis must be identified.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.